Dipòsit Digital de Documents de la UAB 55 registres trobats  1 - 10següentfinal  anar al registre: La cerca s'ha fet en 0.00 segons. 
1.
17 p, 921.2 KB Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes / Sauta, Elisabetta (Humanitas Clinical and Research Center (Itàlia)) ; Robin, Marie (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ; Bersanelli, Mateo (Department of Biomedical Sciences. Humanitas University) ; Travaglino, Erica (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Meggendorfer, Manje (Mll Munich Leukemia Laboratory) ; Zhao, Lin-Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ; Caballero Berrocal, Juan Carlos (Hematology Department. Hospital Universitario de Salamanca) ; Sala, Claudia (Experimental. Diagnostic and Specialty Medicine. Dimes) ; Maggioni, Giulia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Bernardi, Massimo (University Vita-Salute San Raffaele (Itàlia)) ; Di Grazia, Carmen (Irccs Ospedale Policlinico San Martino) ; Vago, Luca (University Vita-Salute San Raffaele (Itàlia)) ; Rivoli, Giulia (Irccs Ospedale Policlinico San Martino) ; Borin, Lorenza (Ospedale San Gerardo) ; D'Amico, Saverio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Tentori, Cristina Astrid (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Ubezio, Marta (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Campagna, Alessia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Russo, Antonio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Mannina, Daniele (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Lanino, Luca (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Chiusolo, Patrizia (Università Cattolica Del Sacro Cuore) ; Giaccone, Luisa (Department of Molecular Biotechnology and Health Sciences. University of Turin) ; Voso, Maria Teresa (Tor Vergata University) ; Riva, Maria (Asst Grande Ospedale Metropolitano Niguarda) ; Oliva, Esther Natalie (Grande Ospedale Metropolitano Bianchi Melacrino Morelli) ; Zampini, Matteo (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Riva, Elena (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Nibourel, Olivier (Chu Lille) ; Bicchieri, Marinela (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Bolli, Niccolo (Department of Oncology and Hemato-Oncology. University of Milan) ; Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni Xxiii) ; Passamonti, Francesco (Department of Medicine and Surgery. University of Insubria) ; Savevski, Victor (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Santoro, Armando (Department of Biomedical Sciences. Humanitas University) ; Germing, Ulrich (Department of Hematology. Heinrich-Heine-University. University Clinic) ; Kordasti, Shahram (Hematology Department. DISCLIMO-Università Politecnica Delle Marche) ; Santini, Valeria (University of Florence) ; Diez-Campelo, María (Hospital Universitario de Salamanca) ; Sanz, Guillermo (Hospital Universitario la Fe) ; Sole, F (Institut de Recerca Contra la Leucèmia Josep Carreras) ; Kern, Wolfgang (Mll Munich Leukemia Laboratory) ; Platzbecker, Uwe (University Hospital Leipzig) ; Arenillas, Leonor (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ; Fenaux, Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ; Haferlach, Torsten (Mll Munich Leukemia Laboratory) ; Castellani, Gastone (Experimental. Diagnostic and Specialty Medicine. Dimes) ; Della Porta, Matteo Giovanni (Department of Biomedical Sciences. Humanitas University)
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). [...]
2023 - 10.1200/JCO.22.01784
Journal of Clinical Oncology, Vol. 41 Núm. 15 (20 2023) , p. 2827-2842  
2.
13 p, 1.6 MB Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8 / Toribio-Castelló, Sofía (CIBERONC. Research Group CB16/12/00233) ; Castaño-Díez, Sandra (Hospital Clínic i Provincial de Barcelona) ; Villaverde-Ramiro, Ángela (Universidad de Salamanca) ; Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ; Arnán, Montserrat (Hospital Duran i Reynals (Hospitalet del Llobregat)) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ; Díez-Campelo, María (CIBERONC. Research Group CB16/12/00233) ; del Rey, Mónivs (Hospital Universitario de Salamanca) ; González, Teresa (Hospital Universitario de Salamanca) ; Hernández-Rivas, Jesús María (CIBERONC. Research Group CB16/12/00233)
Trisomy 8 (+8) is the most frequent trisomy in myelodysplastic syndromes (MDS) and is associated with clinical heterogeneity and intermediate cytogenetic risk when found in isolation. The presence of gene mutations in this group of patients and the prognostic significance has not been extensively analyzed. [...]
2023 - 10.3390/cancers15153822
Cancers, Vol. 15 Núm. 15 (august 2023) , p. 3822  
3.
12 p, 801.4 KB The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw / Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Jerez, Andrés (Vall d'Hebron Institut d'Oncologia) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. [...]
2023 - 10.3390/cancers15051483
Cancers, Vol. 15 Núm. 5 (march 2023) , p. 1483  
4.
10 p, 1.3 MB Two-Time Multiplexed Targeted Next-Generation Sequencing Might Help the Implementation of Germline Screening Tools for Myelodysplastic Syndromes/Hematologic Neoplasms / Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Risueño, Ruth M. (University of Atlántico Medio, Las Palmas) ; Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Next-generation sequencing (NGS) tools have importantly helped the classification of myelodysplastic syndromes (MDS), guiding the management of patients. However, new concerns are under debate regarding their implementation in routine clinical practice for the identification of germline predisposition. [...]
2023 - 10.3390/biomedicines11123222
Biomedicines, Vol. 11 Núm. 12 (december 2023)  
5.
30 p, 7.3 MB Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy / Campillo-Marcos, Ignacio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Casado Pelaez, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mata, Caterina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mereu, Elisabetta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Valcárcel, David (Vall d'Hebron Institut d'Oncologia) ; Molero, Antonieta (Hospital Universitari Vall d'Hebron) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tobiasson, Magnus (Karolinska Institutet (Estocolm, Suècia)) ; Hellström-Lindberg, Eva (Karolinska Institutet (Estocolm, Suècia)) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). [...]
2024 - 10.1158/2767-9764.CRC-23-0389
Cancer Research Communications, Vol. 4 Núm. 2 (2024)  
6.
4 p, 551.6 KB Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype / Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tuechler, Heinz (Boltzmann Institute for Leukaemia Research and Hematology) ; Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ; Raynaud, Sophie (Cote d'Azur University) ; Cluzeau, Thomas (Cote d'Azur University) ; Shih, Lee-Yung (Chang Gung University) ; Tung-Liang, Chiang (Chang Gung University) ; Ganster, Christina (University Medical Center Göttingen) ; Shirneshan, Katayoon (University Medical Center Göttingen) ; Haase, Detlef (University Medical Center Göttingen) ; Mascaró, Martí (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Palomo Sanchís, Laura (Vall d'Hebron Institut d'Oncologia) ; Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ; Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ; Trim, Nicola (Birmingham Women's Hospital) ; Jeffries, Sally (Birmingham Women's Hospital) ; Ridgway, Emma (Birmingham Women's Hospital) ; Marconi, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ; Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. [...]
2023 - 10.1002/jha2.651
EJHaem, Vol. 4 (february 2023) , p. 446-449  
7.
14 p, 1.0 MB CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies / Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Barrera, Susana (Universidad de Salamanca) ; Bataller, Alex (Hospital Clínic i Provincial de Barcelona) ; Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ; Elliot, Natalina (John Radcliffe Hospital (Oxford, Regne Unit)) ; O'Byrne, Sorcha (John Radcliffe Hospital (Oxford, Regne Unit)) ; Wang, Guanlin (University of Oxford) ; Rovira, Montse (University of Oxford) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; González-González, María (Universidad de Salamanca) ; Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sorigue, Marc (Universitat Autònoma de Barcelona) ; Bárcena, Paloma (Universidad de Salamanca) ; Zanetti, S. R (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Torrebadell, Montse (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Vega-Garcia, Nerea (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Rives, Susana (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Mallo, Maria del Mar (Universitat Autònoma de Barcelona) ; Sole, F (Universitat Autònoma de Barcelona) ; Mead, Adam J. (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ; Roberts, Irene (Oxford Biomedical Research Centre) ; Thongjuea, Supat (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Psaila, Bethan (Oxford Biomedical Research Centre) ; Juan, Manel (Hospital Clínic i Provincial de Barcelona) ; Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Urbano-Ispizúa, Alvaro (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ribera, Jose-Maria (Universitat Autònoma de Barcelona) ; Orfao, Alberto (Universidad de Salamanca) ; Roy, Anindita (Oxford Biomedical Research Centre) ; Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. [...]
2022 - 10.1182/blood.2021014840
Blood, Vol. 140 (july 2022) , p. 38-44  
8.
14 p, 9.2 MB Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts / Ademà, Vera (The University of Texas MD Anderson Cancer Center) ; Ma, Feiyang (University of Michigan) ; Kanagal-Shamanna, Rashmi (The University of Texas MD Anderson Cancer Center) ; Thongon, Natthakan (The University of Texas MD Anderson Cancer Center) ; Montalban-Bravo, Guillermo (The University of Texas) ; Yang, Hui (The University of Texas) ; Peslak, Scott A. (Children's Hospital of Philadelphia (Pennsilvània)) ; Wang, Feng (The University of Texas MD Anderson Cancer Center) ; Acha, Pamela (Universitat Autònoma de Barcelona) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lockyer, Pamela (The University of Texas MD Anderson Cancer Center) ; Cassari, Margherita (University of Florence) ; Maciejewski, Jaroslaw P. (Cleveland Clinic Foundation) ; Visconte, Valeria (Cleveland Clinic Foundation) ; Gañán-Gómez, Irene (The University of Texas MD Anderson Cancer Center) ; Song, Yuanbin (Sun Yat-sen University Cancer Center) ; Bueso-Ramos, Carlos (The University of Texas MD Anderson Cancer Center) ; Pellegrini, Matteo (University of California) ; Tan, Tuyet M. (Univerity of California San Diego) ; Bejar, Rafael (Univerity of California San Diego) ; Carew, Jennifer S. (University of Arizona Cancer Center) ; Halene, Stephanie (Yale University School of Medicine) ; Santini, Valeria (University of Florence) ; Al-Atrash, Gheath (The University of Texas MD Anderson Cancer Center) ; Clise-Dwyer, Karen (The University of Texas MD Anderson Cancer Center) ; Garcia-Manero, Guillermo (The University of Texas MD Anderson Cancer Center) ; Blobel, Gerd A. (Children's Hospital of Philadelphia (Pennsilvània)) ; Colla, Simona (The University of Texas MD Anderson Cancer Center)
SF3B1 -mutant MDS-RS is associated with buildup of erythroid progenitor cells upregulating EIF2AK1-associated heme deficiency response and autophagy genes. Targeting EIF2AK1 relieves the dysregulated progenitor phenotype. [...]
2022 - 10.1158/2643-3230.BCD-21-0220
Blood Cancer Discovery, Vol. 3 (august 2022) , p. 554-567  
9.
12 p, 1.0 MB Guiding the global evolution of cytogenetic testing for hematologic malignancies / Akkari, Yassmine M.N. (Departments of Cytogenetics and Molecular Pathology. Legacy Health (Estats Units d'Amèrica)) ; Baughn, Linda B. (Mayo Clinic) ; Dubuc, Adrian M. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ; Smith, Adam C. (University of Toronto) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Dal Cin, Paola (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ; Diez-Campelo, María (Instituto de Investigación Biomédica de Salamanca) ; Gallego, Marta S. (Italian Hospital) ; Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Haase, Detlef (University Medical Center Göttingen) ; Schlegelberger, Brigitte (Department of Human Genetics. Hannover Medical School) ; Slavutsky, Irma (Institute of Experimental Medicine) ; Mecucci, Cristina (Hematology University of Perugia) ; Levine, Ross L. (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ; Hasserjian, Robert P. (Massachusetts General Hospital (Boston)) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Levy, Brynn (Columbia University Medical Center) ; Xu, Xinjie (Mayo Clinic) ; Universitat Autònoma de Barcelona
2022 - 10.1182/blood.2021014309
Blood, Vol. 139 Núm. 15 (14 2022) , p. 2273-2284  
10.
7 p, 1.3 MB Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL) / Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; González-Gil, Celia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Haferlach, Claudia (MLL Munich Leukemia Laboratory) ; Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ; Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ; Barba, Pere (Hospital Universitari Vall d'Hebron) ; Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ; Moreno, María-José (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Martínez-Carballeira, Daniel (Hospital Universitario Central de Asturias) ; Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ; Vives Polo, Susana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; González-Campos, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ; Mercadal, Santiago (Hospital Duran i Reynals (Hospitalet del Llobregat)) ; Artola, Maria Teresa (Hospital de Donostia (Sant Sebastià, País Basc)) ; Cladera, Antonia (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Bermúdez, Arancha (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Martínez-Sánchez, Pilar (Hospital Universitario 12 de Octubre (Madrid)) ; Amigo, María-Luz (Hospital General Universitario Morales Meseguer (Múrcia)) ; Monsalvo, Silvia (Hospital General Universitario Gregorio Marañón) ; Novo, Andrés (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Cervera, Marta (Hospital Universitari Joan XXIII de Tarragona) ; García-Guiñon, Antonio (Hospital Arnau de Vilanova (València)) ; Ciudad Pizarro, Juana (Instituto de Investigación Biomédica de Salamanca) ; Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ; Hernández Rivas, Jesús María (Hospital Clínico Universitario (Salamanca)) ; Granada, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Haferlach, Torsten (MLL Munich Leukemia Laboratory) ; Orfao, Alberto (Instituto de Investigación Biomédica de Salamanca) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. [...]
2021 - 10.1016/j.leukres.2021.106612
Leukemia Research, Vol. 109 (october 2021) , p. 106612  

Dipòsit Digital de Documents de la UAB : 55 registres trobats   1 - 10següentfinal  anar al registre:
Vegeu també: autors amb noms similars
2 Sole, F,
11 Sole, F.
11 Solé, F.
1 Solé, Francisco
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.